Ignite Creation Date:
2025-12-24 @ 6:44 PM
Ignite Modification Date:
2026-02-27 @ 10:01 AM
Study NCT ID:
NCT02173457
Status:
COMPLETED
Last Update Posted:
2019-10-25
First Post:
2014-06-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
Sponsor:
Chipscreen Biosciences, Ltd.
Organization:
Study Overview
Official Title:
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial
Status:
COMPLETED
Status Verified Date:
2019-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CMAS
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with Sitagliptin.
Detailed Description:
The efficacy and safety will be compared between Chiglitazar and Sitagliptin after treatment of 24 weeks.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: